Author(s):
Ashwini Mandawade, Pruthvirajsing Pardeshi, Sukhsagar Khairnar, Ganesh Sonawane, Sunil Mahajan
Email(s):
ashwinimandawade5@gmail.com
DOI:
10.52711/0974-4150.2025.00036 
Address:
Ashwini Mandawade*, Pruthvirajsing Pardeshi, Sukhsagar Khairnar, Ganesh Sonawane, Sunil Mahajan
Department of Pharmaceutical Chemistry, Divine College of Pharmacy, Satana – 423301, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 4,
Year - 2025
ABSTRACT:
This study aims to evaluate and analyze the pharmacokinetic, bioavailability, and toxicity profiles of selected marketed antidiabetic agents using in silico tools, with the objective of validating their clinical utility, identifying potential areas for optimization, and demonstrating the efficiency of computational approaches in drug evaluation and development. Drugs such as Metformin, Tolbutamide, and Glimepiride were analyzed for gastrointestinal absorption, blood-brain barrier permeability, and interactions with CYP450 enzymes. Most agents demonstrated favourable absorption and compliance with Lipinski’s Rule of Five, indicating suitability for oral use. Toxicity predictions using ProTox 3.0 revealed organ-specific risks: Pioglitazone and Acarbose were associated with potential hepatotoxicity, while Sitagliptin and Teneligliptin showed a likelihood of neurotoxicity. Metformin emerged as the safest drug with minimal respiratory toxicity risk. These findings highlights the value of in silico methods in evaluating pharmacological properties and toxicological risks, offering critical insights for optimizing antidiabetic therapy and aiding physicians in informed prescribing decisions for diabetic patients.
Cite this article:
Ashwini Mandawade, Pruthvirajsing Pardeshi, Sukhsagar Khairnar, Ganesh Sonawane, Sunil Mahajan. In Silico Drug-Likeness, ADMET, Toxicity Profiling of Clinically Relevant Antidiabetic agents. Asian Journal of Research in Chemistry.2025; 18(4):235-2. doi: 10.52711/0974-4150.2025.00036
Cite(Electronic):
Ashwini Mandawade, Pruthvirajsing Pardeshi, Sukhsagar Khairnar, Ganesh Sonawane, Sunil Mahajan. In Silico Drug-Likeness, ADMET, Toxicity Profiling of Clinically Relevant Antidiabetic agents. Asian Journal of Research in Chemistry.2025; 18(4):235-2. doi: 10.52711/0974-4150.2025.00036 Available on: https://www.ajrconline.org/AbstractView.aspx?PID=2025-18-4-5
REFERENCES:
1. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. 2021.
2. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019; 157: 107843.
3. Pansare K, Upasani C, Upaganlwar A, Sonawane G, Patil C. Pre-clinical study of lycopene alone and in combination with olive oil in streptozotocin-induced diabetic nephropathy. Vidyabharati Int Interdiscip Res J (Spec Issue). 2021 Aug; 320-332.
4. Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharmacol Ther. 2017; 101(5): 535-547.
5. Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013; 5: 6.
6. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009; 32(1): 193-203.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24): 2457-2471.
8. Lagorce D, Sperandio O, Baell JB, et al. FAF-Drugs3: A web server for compound property calculation and structure-based virtual screening. Nucleic Acids Res. 2015; 43(W1): W200-W207.
9. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness, and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7(1): 42717.
10. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015; 58(9): 4066-4072.
11. Pathak S, Mishra A, Sonawane G, Sonawane K, Rawat S, Raizaday A, Singh SK, Gupta G. In silico pharmacology. In: Computational Approaches in Drug Discovery, Development and Systems Pharmacology. Academic Press. 2023; 1-52.
12. Sonawane G, Sharma S, Gilhotra R. In silico analysis of 1,3,4-oxadiazoles as potential BCL-2 inhibitor for cancer treatment. Asian J Chem. 2024; 36(5): 1072-1088.
13. Sonawane G, Sharma S, Gilhotra R. Synthesis, characterization and pharmacological screening of 1,3,4-oxadiazoles. Asian J Chem. 2024; 36(6): 1436-1446.